Literature DB >> 2805404

Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model.

W K Bleeker1, J Agterberg, G Rigter, N van Rooijen, J C Bakker.   

Abstract

Intravenous administration of certain immunoglobulin preparations may cause severe adverse reactions, especially in hypogammaglobulinaemic patients. Because the exact mechanism of the adverse reactions is still unknown, we investigated the severe, prolonged hypotension induced in anaesthetized rats on rapid i.v. infusion of standard immunoglobulin preparations. The hypotensive response was previously shown to be associated with IgG aggregates in the preparations but independent of complement activation. We found that the hypotension could be prevented by treating the rats with a specific receptor antagonist of platelet-activating factor; or by depletion of the macrophages of the rats; or by pretreatment with monomeric IgG. This provided evidence that the hypotension is initiated by interaction of IgG-aggregates with Fc-receptors on macrophages, leading to the production of platelet-activating factor. We conclude that the rat model provides a sensitive and reproducible test system for macrophage-activating properties of immunoglobulin preparations for i.v. administration which may lead to vasoactive side effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2805404      PMCID: PMC1542048     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Evaluating the quality of immunoglobulin G preparations for intravenous therapy.

Authors:  U E Nydegger
Journal:  Vox Sang       Date:  1985       Impact factor: 2.144

Review 2.  Intravenous immunoglobulins: pharmacological aspects and therapeutic use.

Authors:  A Hässig
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

3.  The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3.

Authors:  C D Dijkstra; E A Döpp; P Joling; G Kraal
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

4.  Modulation of mononuclear phagocyte function by intravenous gamma-globulin.

Authors:  R P Kimberly; J E Salmon; J B Bussel; M K Crow; M W Hilgartner
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

5.  Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. Ultrastructural aspects of elimination of marginal zone macrophages.

Authors:  N van Rooijen; R van Nieuwmegen; E W Kamperdijk
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1985

6.  Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates.

Authors:  G Doekes; L A Vanes; M R Daha
Journal:  Immunology       Date:  1982-04       Impact factor: 7.397

7.  Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study.

Authors:  T W Jungi; M Santer; P G Lerch; S Barandun
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

8.  Hypotensive effects of plasma protein fraction. The relation between prekallikrein activator, bradykinin generation, and blood pressure in an animal model.

Authors:  W K Bleeker; R F Van Rosevelt; J G Ufkes; J A Loos; J A Van Mourik; J C Bakker
Journal:  J Lab Clin Med       Date:  1982-10

9.  Inhibition of the vascular actions of IgG aggregates by BN 52021, a highly specific antagonist of paf-acether.

Authors:  M Sánchez-Crespo; S Fernández-Gallardo; M L Nieto; J Baranès; P Braquet
Journal:  Immunopharmacology       Date:  1985-10

10.  trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor.

Authors:  S B Hwang; M H Lam; T Biftu; T R Beattie; T Y Shen
Journal:  J Biol Chem       Date:  1985-12-15       Impact factor: 5.157

View more
  7 in total

1.  Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis.

Authors:  Eldad A Hod; Set A Sokol; James C Zimring; Steven L Spitalnik
Journal:  Int J Clin Exp Pathol       Date:  2008-05-30

2.  Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis.

Authors:  A C Savoy; D M Lupan; P B Manalo; J S Roberts; A M Schlageter; L C Weinhold; T R Kozel
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

3.  Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function).

Authors:  B Jenei; G Lázár; K Bartha; G A Medgyesi
Journal:  Agents Actions       Date:  1991-03

4.  Prevention and treatment of influenza with hyperimmune bovine colostrum antibody.

Authors:  Wy Ching Ng; Victor Wong; Brian Muller; Grant Rawlin; Lorena E Brown
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

5.  Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice.

Authors:  Brendon J Hanson; Adrianus C M Boon; Angeline P C Lim; Ashley Webb; Eng Eong Ooi; Richard J Webby
Journal:  Respir Res       Date:  2006-10-14

Review 6.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

7.  Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.

Authors:  Jiahai Lu; Zhongmin Guo; Xinghua Pan; Guoling Wang; Dingmei Zhang; Yanbin Li; Bingyan Tan; Liping Ouyang; Xinbing Yu
Journal:  Respir Res       Date:  2006-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.